A prospective, controlled, randomized, double blind, comparative, parallel,2-arm study to evaluate the efficacy and safety of Pitavastatin (4 mg) Vs. Atorvastatin (20 mg) in Dyslipidemic patients associated with hypertension, diabetes and / coronary artery disease.

Dr Chetan Yuvraj Patil0 个研究点目标入组 100 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.Patients suffering from Dyslipidemia according to NCEP ATP III Guidelines (National Cholesterol Education Program, Adult Treatment Panel III) (LDL-C greater than or equal to 130 mg/dl, Total cholesterol- TC greater than or equal to 240 mg/dl) and associated with hypertension, diabetes and / coronary artery disease only.
•2.Dyslipidemic patients, newly diagnosed or uncontrolled on monotherapy ,
•3.Non-pregnant, non-lactating female
•4.Have given informed consent.

•1.History of muscular or neuromuscular disease of any type
•2.H/O chronic liver diseases
•3.Impaired renal function
•4.Concomitant medications such a cyclosporine A, gemfibrozil, clarithromycin, rafamycin, rafampicin, which might significantly cause drug-drug interaction.
•5.History of drug allergy to study drugs related group
•6.History of HIV infection
•7.Diagnosed case any malignant condition, psychiatric illness
•8.Patients addicted to alcohol
•9.Exposure to any investigational new drug within 30 days of study entry or ingestion of any drug known to be toxic to a major organ system.
•10.Serum total creatine kinase > 5x

发起方

Dr Chetan Yuvraj Patil